Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
13 hedge funds and large institutions have $169K invested in Avenue Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
222% more capital invested
Capital invested by funds: $52.4K → $169K (+$116K)
7% less funds holding
Funds holding: 14 → 13 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$106K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$23.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.4K |
| 4 |
Jane Street
New York
|
+$4.73K |
| 5 |
HF
HRT Financial
New York
|
+$3.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$14.4K |
| 2 |
Millennium Management
New York
|
-$2.85K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.76K |
| 4 |
BlackRock
New York
|
-$202 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$174 |
ATXI Hedge Fund Activity: Q1 2024 in Review
13 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q1 2024, worth a combined $169K — up 222% from $52.4K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ATXI and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $106K. The largest seller was Citadel Advisors, exiting entirely with an estimated $14.4K sold.
- 13 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q1 2024, down from 14 in Q4 2023.
- Funds reported $169K of Avenue Therapeutics, Inc. Common Stock stock for Q1 2024, up 222% quarter-over-quarter.
- 3 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q1 2024 and 4 closed out, a net change of -1 holder.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q1 2024 was Sabby Management, an estimated $106K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q1 2024 was Citadel Advisors, an estimated $14.4K sold.
Based on aggregated 13F filings for Q1 2024.